This is a bar graph that illustrates the number of existing and first generic drug application approvals per fiscal year, 2010-2019. 2010 2011 2012 2013
Chart: Price Changes by Product, Post Blueprint Period in 2017 Compared to the Same Time Period in 2018
Home Generics and Biosimilars Reports to Congress Medicare Part B Research Prescription Drug Pricing: ASPE Resources Related to Safe Harbor Rule
Home Generics and Biosimilars Reports to Congress Medicare Part B Research Medicare Part B Drugs: Trends in Spending and Utilization, 2006-2017
Home Generics and Biosimilars Reports to Congress Medicare Part B Research
Home Generic Drug Markets and Pricing Reports to Congress Medicare Part B Research
Part D Gross Drug Costs, 2016, $US Billions MultiSource: $42.7 Brands: $8.7 Savings: $ Single souce: $102.0 Generics: $34.0 Spending if fully substituted: $5.9 Return to the Generic and Biosimilars page .
Home Generics and Biosimilars Reports to Congress Medicare Part B Research Comparing Insulin Prices in the U.S. to Other Countries
Pharmaceutical supply chain includes 6 parties: payers, consumers, pharmacies, pharmacy benefits manager, distributor, and drug manufacturer.
Dramatic growth in the use of generic drugs has generated substantial savings for American consumers. To examine how the Department of Health and Human Services (HHS) can encourage the use of generic drugs, the Assistant Secretary for Planning and Evaluation (ASPE) examined barriers to, and opportunities for, expanding the use of generic drugs.
Unlike most conventional drugs, biological products are usually large, complex molecules that are produced by living organisms. These commercially engineered biologics currently account for billions of dollars in health care spending. Starting early last century, Congress has regulated most biologics separately from small molecules under the Bio